INmune Bio Reports Q2 2026 Results and Pipeline Progress
BOCA RATON, Fla., August 6, 2026 INmune Bio Inc. reported its second quarter 2026 financial results while highlighting significant...
Alzheimer’s Disease
Advertisement
MMI Advances REMIND Alzheimer’s Study After FDA IDE Approval
JACKSONVILLE, Fla., July 30, 2026 Medical Microinstruments (MMI) announced that the U.S. Food and Drug Administration (FDA) has approved...
Cipla Receives FDA Nod for Generic Advair Diskus
MUMBAI, India and WARREN, N.J., July 28, 2026 Cipla Limited and its wholly owned subsidiary Cipla USA Inc. have...
CORE Biomedicine Secures $21M Series A Funding
BOSTON, TOKYO and SUZHOU, July 28, 2026 CORE Biomedicine, a biotechnology company advancing lineage-based precision oncology therapeutics, has announced...
C2N Diagnostics Expands PrecivityAD2 Use in UK Alzheimer’s Diagnosis
ST. LOUIS, July 29, 2026 C2N Diagnostics, LLC announced that researchers in the United Kingdom are integrating its PrecivityAD2®...
Advertisements
Co-Diagnostics Advances Ebola Testing Innovation Globally
SALT LAKE CITY, July 28, 2026 Co-Diagnostics, Inc. has announced two significant milestones that strengthen global preparedness against Ebola...
Dasher Neuroscience Advances YA-101 Phase 2 Trial
TAIPEI, July 28, 2026 Dasher Neuroscience Holdings Inc. has successfully completed patient enrollment in its global Phase 2 clinical...
ProMIS Neurosciences Reports Positive Phase 1b PMN310 Interim Data
CAMBRIDGE, Mass., July 28, 2026 ProMIS Neurosciences Inc. announced positive blinded six-month interim safety and biomarker data from the...
Acadia Secures FDA Fast Track for Alzheimer’s Psychosis Drug
San Diego, California, USA | July 21, 2026 Acadia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA)...
Cumulus Unveils AI Tool for Alzheimer’s Trial Screening
TORONTO, Canada, July 15, 2026 Cumulus Neuroscience has presented new clinical findings at the Alzheimer’s Association International Conference (AAIC)...
Advertisement
